BPA
CRSP icon

Beacon Pointe Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Beacon Pointe Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$617K Sell
11,307
-778
-6% -$41K ﹤0.01% 1242
2026
Q1 		$575K Sell
12,085
-851
-7% -$44.9K ﹤0.01% 1234
2025
Q4 		$678K Buy
12,936
+110
+0.9% +$6.59K ﹤0.01% 964
2025
Q3 		$831K Buy
12,826
+5,380
+72% +$309K 0.01% 833
2025
Q2 		$362K Buy
+7,446
New +$288K ﹤0.01% 989
2024
Q2 		– Sell
-6,334
Closed -$432K – 1295
2024
Q1 		$432K Buy
6,334
+2,566
+68% +$184K ﹤0.01% 971
2023
Q4 		$236K Buy
+3,768
New +$208K ﹤0.01% 1157

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Beacon Pointe Advisors's CRSP Position: Q2 2026 in Review

Beacon Pointe Advisors reduced its CRISPR Therapeutics (CRSP) stake by 6.4% in Q2 2026, selling an estimated $41K and leaving 11,307 shares worth $617K. The position accounts for ﹤0.01% of the portfolio, ranked #1242.

Beacon Pointe Advisors first reported a position in CRSP in Q4 2023 and has held it in 7 quarters since. The position peaked at $831K in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Beacon Pointe Advisors held 11,307 shares of CRISPR Therapeutics worth $617K as of Q2 2026.
  • Beacon Pointe Advisors sold 778 CRISPR Therapeutics shares in Q2 2026, an estimated $41K.
  • CRISPR Therapeutics made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1242 holding.
  • Beacon Pointe Advisors first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • Beacon Pointe Advisors's CRISPR Therapeutics position peaked at $831K in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.